Crescent Biopharma, Inc. (CBIO)
| Market Cap | 225.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 14.95M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,309 |
| Open | 15.52 |
| Previous Close | 15.29 |
| Day's Range | 15.00 - 15.60 |
| 52-Week Range | 11.06 - 21.40 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 25.00 (+66.67%) |
| Earnings Date | Aug 23, 2025 |
About CBIO
Crescent Biopharma, Inc. operates as a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company was incorporated in 2024 and is based in USA. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CBIO stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 66.67% from the latest price.
News
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, In...
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to a...
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics,...
Crescent Biopharma Appoints David Lubner to Board of Directors
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology com...
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 b...
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc...
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”), a privately held biotechnol...
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer ...
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics: Is No News Bad News?
GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia. GLYC's lead candidate, uproleselan, has shown promising results in early-stage clinical trials ...
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, ...
GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript
GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
GlycoMimetics Can Become A Game Changer In Blood Cancers
GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor p...
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on We...